The symposium, titled "Adaptive MR Image-Guided Radiotherapy: Experience & Applications in Routine Clinical Practice," will highlight various topics ranging from technical considerations such as linear accelerator system commissioning and quality assurance, to clinical information, such as clinical trials and protocols. Presenters will also discuss clinical experience and early outcomes data, with particular emphasis on the practice of on-table adaptive radiotherapy.
More than 10 clinicians will present their MR image-guided radiation therapy experience. Speakers include clinicians from top tier institutions including
The event will conclude with a tour of the MRIdian® Linac MR image-guided radiation therapy system at the symposium's clinical host institution,
MR image-guided radiotherapy represents a major shift in the field of radiation oncology by using diagnostic-quality, high-definition anatomical image detail that's unavailable with conventional image-guided radiotherapy (IGRT) technologies. By relying on the anatomical detail now visible with MR soft tissue imaging, clinicians are able to see changes to the tumor and surrounding tissues and quickly adjust for them each day while the patient is on the treatment table. Combined, MR imaging and the ability to adapt treatments dynamically provide clinicians with the tools capable of improving tumor targeting precision and thus allow for delivery of higher, and potentially more effective, radiation doses.
"We are excited to be a part of such an important educational event, featuring some of the foremost experts on MRI-guided radiation therapy and are thrilled to welcome attendees to our new state-of-the-art cancer center to tour our next generation MRIdian Linac system," said
The symposium is sponsored by
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the advancement of science, and the ability of MRI-guided radiation therapy programs to enable more treatment options, improved tumor targeting precision and higher, more effective, radiation dose. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue
View original content with multimedia:http://www.prnewswire.com/news-releases/world-leading-oncologists-to-meet-in-miami-for-adaptive-mr-image-guided-radiotherapy-symposium-300653373.html
Michael Saracen, Vice President, Marketing, ViewRay, Inc., Phone: +1 408-242-2994, Email: firstname.lastname@example.org